Lisata Therapeutics (LSTA) Projected to Announce Quarterly Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) will likely be issuing its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.1250) per share and revenue of $0.66 million for the quarter.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Thursday, August 6th. The company reported ($0.32) EPS for the quarter.

Lisata Therapeutics Stock Performance

NASDAQ LSTA opened at $1.06 on Thursday. The company has a market capitalization of $11.45 million, a PE ratio of -0.65 and a beta of 0.94. The business’s fifty day moving average is $1.40 and its 200 day moving average is $2.99. Lisata Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $5.07.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About Lisata Therapeutics

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.